Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines

Scipher Medicine

Attachments

2022: Scipher Medicine collects $110M for its drug-matching blood tests
2022: The financing was led by Cowen Healthcare Investments. Other investors both old and new included Neuberger Berman, Hitachi Ventures, Laurion Capital, Monashee Investment Management, Khosla Ventures, Optum Ventures, Echo Health Ventures and Alumni Ventures, as well as Northpond Ventures and aMoon
Alif Saleh CEO, SCIPHER MEDICINE (2021)
First-of-its kind blood based molecular signature test identifies a patient’s unique disease biology to determine which drug actually targets the disease, allowing providers and payers to make the right therapy decision to reach treatment goals.
Founded 2013
Real world clinico-genomic data collected from our tests and analyzed by our AI platform reveals novel drug targets specific to biologically similar patient populations.
Uses a patient’s own molecular data to ensure optimal therapy is prescribed from day one, improving lives and saving money
Waltham, Massachusetts